stockrowPenumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) Return on assets
Penumbra, Inc.'s return on assets over the twelve months to 30 September 2026 was 8.33%, down 2.2 percentage points from fiscal 2025 (10.6%). Over the past ten years it has ranged from −2.11% (fiscal 2020) to 10.6% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 10.6% | 9.67 |
| FY2024 | 0.91% | (5.30) |
| FY2023 | 6.21% | 6.36 |
| FY2022 | −0.15% | (0.66) |
| FY2021 | 0.51% | 2.62 |
| FY2020 | −2.11% | (10.32) |
| FY2019 | 8.21% | 6.88 |
| FY2018 | 1.33% | 0.14 |
| FY2017 | 1.19% | (3.99) |
| FY2016 | 5.18% | 4.62 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PODD Insulet Corporation compare | 13.3% |
| GMED Globus Medical, Inc. compare | 10.5% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 9.99% |
| BIO Bio-Rad Laboratories, Inc. compare | 9.99% |
| PEN Penumbra, Inc. | 8.33% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −2.73% |
| TXG 10x Genomics compare | −7.47% |
| GKOS Glaukos Corporation compare | −17.2% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement